Press Release

Applied Protein Sciences and Biomodels Collaborate to Boost

Supportive Cancer Care
04.28.09, 7:58 PM ET

BusinessWire - Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that
it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS
expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program
later this year.

"We are very excited about partnering with Biomodels," said Aman Johar, CEO of APS. "This relationship allows us
flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A
full-scale collaboration extends our research platform and provides access to leading scientists and researchers.
Biomodels' proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can
be the standard of care for preventing mucositis - saving over $2 billion annually in hospitalization costs."

"Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related
therapeutic areas using appropriate validated models," said Edward Fey, Managing Partner of Biomodels. "This alliance
represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of
early stage pharmaceutical companies," Fey adds.

Mucositis remains an unmet medical need and APS products may become the "standard of care" for solid tumor patients
undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis
patients said that physicians need to be educated more about its treatments. There are currently no approved medications
for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to
encompass all aspects of supportive oncology care.

About Applied Protein Sciences

APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of
mucositis. With APS' products, patients can remain on chemotherapy or radiation for longer, significantly increasing their
survival. In addition to mucositis, APS drug platform includes candidates for proctitis and IBD - significant unmet medical
needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued US and
worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned
and investors include Innovation Management Sciences.

www.appliedprotein.com

About Biomodels

Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development
process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the
process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of
inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and
added confidence in the design of clinical studies, all of which conveys substantial cost savings.

www.biomodels.com

SOURCE: Applied Protein Sciences

Applied Protein Sciences Amanjyot S. Johar, 650-969-8300 info@appliedprotein.com or Biomodels Edward G. Fey, 857-
228-1100 info@biomodels.com
 Print Back to story

Press Release Source: Applied Protein Sciences

Applied Protein Sciences and Biomodels Collaborate to Boost

Supportive Cancer Care
On Tuesday April 28, 2009, 7:58 pm EDT

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it
has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop
proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year.

“We are very excited about partnering with Biomodels,” said Aman Johar, CEO of APS. “This relationship allows us flexibility to customize our pre-clinical
studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to
leading scientists and researchers. Biomodels’ proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be
the standard of care for preventing mucositis – saving over $2 billion annually in hospitalization costs.”

“Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate
validated models,” said Edward Fey, Managing Partner of Biomodels. “This alliance represents a new business model for the outsourcing of pre-clinical
services and is designed to fulfill the specific needs of early stage pharmaceutical companies,” Fey adds.

Mucositis remains an unmet medical need and APS products may become the “standard of care” for solid tumor patients undergoing cancer treatment.
Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to be educated more about its
treatments. There are currently no approved medications for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can
be scaled to encompass all aspects of supportive oncology care.

About Applied Protein Sciences

APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS’ products, patients
can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to mucositis, APS drug platform includes candidates for
proctitis and IBD - significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued
US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include
Innovation Management Sciences.

www.appliedprotein.com

About Biomodels

Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in
screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and
cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the
clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings.

www.biomodels.com

Contact:

Applied Protein Sciences

Amanjyot S. Johar, 650-969-8300
info@appliedprotein.com
or
Biomodels
Edward G. Fey, 857-228-1100
info@biomodels.com

Copyright © 2008 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's
personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database, or redistribution
in a computer network is strictly forbidden.

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Send Feedback

Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of
inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on
or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review
any information or data contained herein.
Print | Close this window

Applied Protein Sciences and Biomodels

Collaborate to Boost Supportive Cancer
Care
Tue Apr 28, 2009 7:58pm EDT

MOUNTAIN VIEW, Calif.--(Business Wire)--

Applied Protein Sciences, a biotechnology start-up focused on preventing
mucositis, announced today that it has entered into a strategic alliance with
Biomodels. This alliance allows speedier product development and helps APS
expand its pipeline to develop proprietary drugs for mucositis, proctitis and
IBD. APS expects to launch its clinical program later this year.

"We are very excited about partnering with Biomodels," said Aman Johar, CEO of
APS."This relationship allows us flexibility to customize our pre-clinical
studies, maintain our clinical end-points and effectively utilize capital
resources. A full-scale collaboration extends our research platform and provides
access to leading scientists and researchers. Biomodels` proven models reliably
predict clinical success in an extremely complex field of mucositis. APS
products can be the standard of care for preventing mucositis - saving over $2
billion annually in hospitalization costs."

"Together Biomodels and APS will finalize oral mucositis studies and also
rapidly test a number of mechanistically-related therapeutic areas using
appropriate validated models," said Edward Fey, Managing Partner of Biomodels.
"This alliance represents a new business model for the outsourcing of
pre-clinical services and is designed to fulfill the specific needs of early
stage pharmaceutical companies," Fey adds.

Mucositis remains an unmet medical need and APS products may become the
"standard of care"for solid tumor patients undergoing cancer treatment.
Mucositis affects over 400,000 patients annually. In a recent survey, 66% of
mucositis patients said that physicians need to be educated more about its
treatments. There are currently no approved medications for preventing
mucositis. This collaboration boosts APS efforts to build a technology platform
that can be scaled to encompass all aspects of supportive oncology care.

About Applied Protein Sciences

APS is developing proprietary proteins that help with the growth of the mucosal
tissue, thereby preventing the onset of mucositis. With APS` products, patients
can remain on chemotherapy or radiation for longer, significantly increasing
their survival. In addition to mucositis, APS drug platform includes candidates
for proctitis and IBD - significant unmet medical needs in supportive oncology
care. APS aims to secure orphan drug status and has a broad portfolio of issued
US and worldwide patents rights. APS recently released a mechanism of action for
its drug candidates. APS is privately owned and investors include Innovation
Management Sciences.

www.appliedprotein.com

About Biomodels

Biomodels is a preclinical CRO helping biotechnology companies enter clinical

trials phase of the drug development process. Biomodels specializes in screening
studies to evaluate efficacy and define mechanism of action to expedite the
process. Over the years Biomodels core competencies in oncology and cancer
supportive care include a range of inflammatory and mucosal diseases. The net
effects are preclinical data that are meaningfully translatable to the clinic
and added confidence in the design of clinical studies, all of which conveys
substantial cost savings.
www.biomodels.com

Applied Protein Sciences

Amanjyot S. Johar, 650-969-8300
info@appliedprotein.com
or
Biomodels
Edward G. Fey, 857-228-1100
info@biomodels.com

Copyright Business Wire 2009

© Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content
from this website for their own personal and non-commercial use only. Republication or
redistribution of Thomson Reuters content, including by framing or similar means, is expressly
prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo
are registered trademarks or trademarks of the Thomson Reuters group of companies around the
world.

Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and
disclosure of relevant interests.